Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Obesity-Related HFpEF
NCT07554638Phase 4Recruiting
- Sponsor
- Columbia University
- Start
- Aug 2026
- Primary completion
- Apr 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tirzepatide in heart failure with preserved ejection fraction (HFpEF) and obesity, sponsored by Columbia University. Primary endpoint: Plasma volume at 12 months. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on NCT07554638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554638.